Article
Factors Associated With Guideline-recommended KRAS Testing in Colorectal Cancer Patients: A Population-based Study.
American journal of clinical oncology - 1 Oct 2017
Charlton Mary E, Karlitz Jordan J, Schlichting Jennifer A, Chen Vivien W, Lynch Charles F
Abstract excerpt
OBJECTIVES: Response to epidermal growth factor receptor inhibitors is poorer among stage IV colorectal cancer (CRC) patients with KRAS mutations; thus KRAS testing is recommended before treatment. KRAS testing was collected by Surveillance, Epidemiology, and End Results (SEER) registries for 2010 CRC cases, and our goal was to provide the first population-based estimates of testing in the United States. METHODS:...
Topics
- Adult
- Aged
- Aged, 80 and over
- Colorectal Neoplasms
- DNA Mutational Analysis
- Female
- Humans
- Middle Aged
- Mutation
- Proto-Oncogene Proteins p21(ras)
- SEER Program
- Survival Analysis
- United States